Prospective randomized control study of efficacy of transcatheter arterial chemoembolization (TACE) with Miriplatin vs. Epirubicin for recurrent hepatocellular carcinoma after TACE.
Phase 2
- Conditions
- hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000005782
- Lead Sponsor
- Kanazawa University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 70
Inclusion Criteria
Not provided
Exclusion Criteria
1)Extrahepatic metastasis 2)Patients with active double cancer. 3)Patients with remarkable findings of A-P shunt and/or A-V shunt. 4)Patients with serious allergic symptoms with iodine. 5)Pregnant, lactating women or women with suspected or desired pregnancy 6)Patients who are concluded to be inappropriate to participate in this study by their physicians.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method